Pediatric ulcerative colitis: Current treatment approaches including role of infliximab

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 125-134

  Bradley, Gia M ^a   Oliva Hemker, Maria ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 aminosalicylates; Anti tumor necrosis factor Agents; Corticosteroids; Cyclosporine; Inflammatory bowel disease; Thiopurine immunomodulators

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; CALCINEURIN INHIBITOR; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; PLACEBO; PREDNISONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; STEROID; SULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ABSCESS; ADRENAL DISEASE; ANOREXIA; ARTHRALGIA; BACTERIAL INFECTION; BLOOD PRESSURE; BONE MARROW SUPPRESSION; CATARACT; CHILD HEALTH CARE; CHRONIC DISEASE; COLITIS; COLON RESECTION; DELAYED HYPERSENSITIVITY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENTERITIS; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GROWTH DISORDER; HEADACHE; HEPATITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ILEITIS; INFECTION; INJECTION SITE REACTION; LARYNX SPASM; LIVER CANCER; LIVER TOXICITY; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MOOD DISORDER; NAUSEA; NEPHROTOXICITY; NONHUMAN; OLIGOSPERMIA; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PANCREATITIS; PHOTOSENSITIVITY DISORDER; PNEUMONIA; PRIMARY HEALTH CARE; RECURRENT DISEASE; REMISSION; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SPLEEN CANCER; T CELL LYMPHOMA; THORAX PAIN; TREATMENT DURATION; TREATMENT PLANNING; TREMOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN;

EID: 84866747687     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Hyams JS. Inflammatory bowel disease. Pediatr Rev. 2005;26(9): 314-320.
2. Cuffari C. Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr. 2006;58(2):139-157.
3. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88(11):995-1000.
4. Hyams J, Davis P, Lerer T, et al. Clinical outcome of ulcerative proctitis in children. J Pediatr Gastroenterol Nutr. 1997;25(2):149-152.
5. Uchida K, Araki T, Toiyama Y, et al. Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis Colon Rectum. 2006;49(1):74-79.
6. Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg. 2007;16(3):164-171.
7. Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis. Expert Opin Pharmacother. 2006;7(14):1907-1918.
8. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am. 2009;38(4):577-594.
9. Quiros JA, Heyman MB, Pohl JF, et al. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. J Pediatr Gastroenterol Nutr. 2009;49(5):571-579.
10. Tolia V, Massoud N, Klotz U. Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. J Pediatr Gastroenterol Nutr. 1989;8(3):333-338.
11. D'Agata ID, Vanounou T, Seidman E. Mesalamine in pediatric inflammatory bowel disease: a 10-year experience. Inflamm Bowel Dis. 1996;2(4):229-235.
12. Heyman MB, Kierkus J, Spenard J, Shbaklo H, Giguere M. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis. 2010;16(11):1931-1939.
13. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4(9):1118-1123.
14. Tung J, Loftus EV Jr, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2006;12(12):1093-1100.
15. Oliva-Hemker M, Escher JC, Moore D, et al. Refractory inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr. 2008;47(2):266-272.
16. Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011;106(5):981-987.
17. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 1998;115(4):813-821.
18. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2(9):731-743.
19. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121-1125.
20. Banerjee S, Bishop WP. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center. J Pediatr Gastroenterol Nutr. 2006;43(3):324-330.
21. Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011;106(4):574-588.
22. Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 1995;38(5):474-479.
23. Castro M, Papadatou B, Ceriati E, et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch Surg. 2007;392(2):161-164.
24. Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis. 2011;17(1):22-29.
25. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661-673.
26. Alexander F. Complications of ileal pouch anal anastomosis. Semin Pediatr Surg. 2007;16(3):200-204.
27. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(11): 1202-1209.
28. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218-2227.
29. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med. 2010;10:13.
30. Fujimori S, Gudis K, Mitsui K, et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition. 2009;25(5):520-525.
31. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104(2):437-443.
32. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs. 2007;67(12):1703-1723.
33. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;3:CD005112.
34. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-2476.
35. Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2002;34(3):307-311.
36. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38(3):298-301.
37. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr. 2004;39(2):166-170.
38. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005;11(3): 213-218.
39. Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2007;44(3):312-317.
40. Cucchiara S, Romeo E, Viola F, et al. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig Liver Dis. 2008; 40 Suppl 2:S260-S264.
41. McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol. 2008;42(8):875-879.
42. Tiemi J, Komati S, Sdepanian VL. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. J Pediatr Gastroenterol Nutr. 2010;50(6):628-633.
43. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(4):391-399.
44. Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010;105(6):1430-1436.
45. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 2005;11(5):442-446.
46. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38(5):502-508.
47. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007;13(8):1024-1030.
48. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685-698.
49. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-265.
50. Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(12):1683-1687.
51. Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6(4):659-666.
52. Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol. 2011;27(4):346-357.
53. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041-1048.
54. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423-432.
55. Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009;15(8):1218-1223.
56. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138(7):2282-2291.